Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The selective noradrenaline re-uptake inhibitor reboxetine may have advantages over the selective serotonin re-uptake inhibitors fluoxetine and citalopram, in effects on sexual function and satisfaction. The effects of reboxetine and paroxetine on sexual function were compared by examining data from the UK centres in an international double-blind flexible-dose parallel-group multi-centre randomized controlled trial of acute treatment of patients with DSM-IV major depression. Patients were randomly assigned to receive reboxetine (4mg b.d.) or paroxetine (20mg mane) using a double-dummy technique to preserve the blind. The dosage could be increased at day 28 (to reboxetine 4mg mane, 6mg nocte; or paroxetine 20mg b.d.). Antidepressant efficacy was assessed by the 21-item Hamilton Rating Scale for Depression (HAM-D) and Clinical Global Impression Scale for Severity (CGI-S) at all study visits, and the Clinical Global Impression of Improvement (CGI-I) at each visit after randomization. Sexual function and satisfaction was assessed by visual analogue scale (VAS) items of the Rush Sexual Inventory completed at baseline and days 28 and 56. There were no significant differences between groups in demographic or clinical features at baseline. There was a gradual reduction in severity of depressive symptoms (reboxetine, 14.3; paroxetine, 12.0: observed case analysis), with no significant differences between groups. There were significant differences ( p 0.05), with advantages for reboxetine, at Week 4 and Week 8 on the VAS item assessing ability to become sexually excited, and non-significant trends with advantages for reboxetine, in frequency of sexual thoughts at Week 4 ( p 0.05) and Week 8 ( p 0.08); and in desire to initiate sexual activity at Week 4 ( p 0.09). Exclusion of patients who had ever experienced sexual dysfunction with any medication prior to participation in this study ( n 10) reduced the statistical significance of the findings, although there were still numerical advantages for reboxetine. Sexual function and satisfaction in depressed patients improves during double-blind acute treatment with reboxetine or paroxetine, but this improvement is greater and more rapid with reboxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Sexual dysfunction associated with antidepressant drugs
Baldwin, D. S. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.457 · Cited by 84
Self-citation
Cited by
Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 588
Core symptoms of major depressive disorder: relevance to diagnosis and treatment
Kennedy, S. H. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.3/shkennedy · Cited by 353
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Antidepressants and sexual dysfunction
Werneke, U., Northey, S., & Bhugra, D. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00890.x · Cited by 176
Metadata
- Authors
- Baldwin, D., Bridgman, K., & Buis, C.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2006-01
- Volume
- 20
- Issue
- 1
- Pages
- 91-96
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2009284028
- Cited by
- 72
- References
- 2
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. https://app.cochat.ai/papers/10.1177/0269881105056666
- The paper
- Baldwin, D., Bridgman, K., & Buis, C. (2006). Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105056666
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.